LEADER 05549nam 22006255 450 001 9910300330703321 005 20200707030317.0 010 $a4-431-54412-7 024 7 $a10.1007/978-4-431-54412-8 035 $a(CKB)3710000000075332 035 $a(EBL)1593271 035 $a(OCoLC)902409311 035 $a(SSID)ssj0001067300 035 $a(PQKBManifestationID)11675218 035 $a(PQKBTitleCode)TC0001067300 035 $a(PQKBWorkID)11080972 035 $a(PQKB)10419991 035 $a(MiAaPQ)EBC1593271 035 $a(DE-He213)978-4-431-54412-8 035 $a(PPN)176126074 035 $a(EXLCZ)993710000000075332 100 $a20131115d2014 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 14$aThe Concise Manual of Apheresis Therapy /$fedited by Eisei Noiri, Norio Hanafusa 205 $a1st ed. 2014. 210 1$aTokyo :$cSpringer Japan :$cImprint: Springer,$d2014. 215 $a1 online resource (416 p.) 300 $aDescription based upon print version of record. 311 $a4-431-54411-9 320 $aIncludes bibliographical references and index. 327 $aPart 1. Principles and Technologies -- Chapter 1. Theoretical background of Apheresis Therapy - Norio Hanafusa -- Chapter 2. Methods to Remove Pathogens - Tamami Tanaka -- Chapter 3. Decision to Prescribe PE, DFPP, or PA- Rei Isshiki -- Chapter 4. Plasma Exchange - Daisuke Katagiri -- Chapter 5. Double Filtration Plasmapheresis - Daisuke Katagri -- Chapter 6. Plasma Adsorption- Yasuyuki Watanabe -- Chapter 7. Cryofiltration - Daisuke Katagiri -- Chapter 8. Double Filtration Plasmapheresis Thermo-mode (DF Thermo)- Mizuki Yamano -- Chapter 9. Plasma Diafiltration - Hajime Nakae -- Chapter 10. Direct Plasma Adsorption - Mayumi Miwa -- Chapter 11. Cytapheresis - Yuki Itoh -- Chapter 12. Cell-free and Concentrated Ascites Reinfusion Therapy - Norio Hanafusa -- Part 2. Therapeutic Details -- Chapter 13. Choice of Apheresis Therapy- Eisei Noiri -- Chapter 14. Determination of Dosage and Frequency of Therapy- Norio Hanafusa -- Chapter 15. Vascular Access- Koji Okamoto -- Chapter 16. Anticoagulants - Tetsushi Yamashita -- Part 3. Complications -- Chapter 17. Hypotension - Tsuyoshi Inoue -- Chapter 18. Bleeding Complications and Reduction of Coagulation Factors- Norio Hanafusa -- Chapter 19. Allergies - Motonobu Nakamura -- Chapter 20. Electrolytes Disorders - Motonobu Nakamura -- Chapter 21. Avoiding Complications during Apheresis - Tetsushi Yamashita -- Chapter 22. Infections - Osamu Yamazaki -- Part 4. Autoimmune Disorders -- Chapter 23. Neurological Diseases- Masao Iwagami -- Chapter 24. Dermatological Disorders- Masao Iwagami -- Chapter 25. Kidney Diseases- Masao Iwagami -- Chapter 26. Rheumatoid Arthritis and Collagen Diseases - Hiroko Kanda -- Chapter 27. Blood type incompatible pregnancies - Norio Hanafusa -- Chapter 28. Multiple Myeloma - Tsuyoshi Inoue -- Chapter 29. Dilated Cardiomyopathy - Yoshifumi Hamasaki -- Part 5. Pathogens with Large Molecular Weight.- Chapter 30. Low Density Lipoprotein Apheresis - Kenjiro Honda -- Chapter 31. Endotoxin Adsorption Therapy - Kent Doi -- Part 6. Diseases Necessary to Supply Coagulation Factors -- Chapter 32. Liver Diseases - Kent Doi.- Chapter 33. Thrombotic Thrombocytopenic Purpura and Thrombotic Microangiopathy - Kenjiro Honda.- Chapter 34. Inflammatory Bowel Diseases - Tsuyoshi Inoue.- Chapter 35. Hepatitis C Virus Infection - Shi Lu.- Chapter 36. Drug Intoxications - Motonobu Nakamura -- Chapter 37. Living Related Kidney Transplantation - Hiroo Kawarazaki -- Chapter 38. Peripheral Blood Stem Cell Transplantation- Naoko Watanabe-Okochi -- Part 7. Pediatric Apheresis -- Chapter 39. Apheresis in Children - Motoshi Hattori. 330 $aThis pocket-sized manual serves as a concise and ideal reference work for therapeutic approaches using apheresis. Covering both basic theory and clinical details to facilitate improved treatment and patient outcomes, the text considers a variety of diseases, including myasthenia gravis, multiple sclerosis, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, nephrotic syndrome, TTP/TMA, dilated cardiomyopathy, and many other conditions. The book also reviews the growing trend toward adopting this unique therapy for a wide range of health management issues such as morbid obesity and/or type 2 diabetes, and for lowering LDL-cholesterol (cholesterol apheresis) in patients unresponsive to medication or lifestyle modification. 606 $aNephrology 606 $aInternal medicine 606 $aBiomedical engineering 606 $aNephrology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33126 606 $aInternal Medicine$3https://scigraph.springernature.com/ontologies/product-market-codes/H33002 606 $aBiomedical Engineering and Bioengineering$3https://scigraph.springernature.com/ontologies/product-market-codes/T2700X 615 0$aNephrology. 615 0$aInternal medicine. 615 0$aBiomedical engineering. 615 14$aNephrology. 615 24$aInternal Medicine. 615 24$aBiomedical Engineering and Bioengineering. 676 $a615.39 702 $aNoiri$b Eisei$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aHanafusa$b Norio$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910300330703321 996 $aConcise Manual of Apheresis Therapy$91521931 997 $aUNINA